THE USE OF A HUMAN MONOCLONAL ANTI-HCV ANTIBODY AS A MEDICAMENT FOR THE THERAPEUTIC TREATMENT AND PREVENTION OF HCV INFECTIONS

摘要

The present invention relates to human monoclonal antibodies capable of recognizing the conformational epitope of the HCV E2 glycoprotein recognized by the e8 Fab and cross-reacting with a plurality of different HCV genotypes, as a medicament for the treatment or prevention of HCV infections. A pharmaceutical composition for the treatment or prevention of HCV infections, comprising an antibody as defined above, preferably the e8 Fab, as well as pharmaceutically acceptable excipients, vehicles or diluents, is also disclosed.